FibroBiologics, Total Current Assets vs Total Current Liabilities Analysis

FBLG Stock   2.25  0.24  11.94%   
FibroBiologics, Common financial indicator trend analysis is much more than just examining FibroBiologics, Common latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether FibroBiologics, Common is a good investment. Please check the relationship between FibroBiologics, Common Total Current Assets and its Total Current Liabilities accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroBiologics, Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Total Current Assets vs Total Current Liabilities

JavaScript chart by amCharts 3.21.15201420162018202020222024500K1M1.5M2M2.5M3M3.5M4M4.5M5M5.5M6M6.5M7M7.5M8M8.5M9M 2M2.5M3M3.5M4M4.5M5M5.5M6M6.5M7M7.5M8M8.5M
JavaScript chart by amCharts 3.21.15Total Current Assetstotal: 25.7MTotal Current Liabilitiestotal: 38.7M

Total Current Assets vs Total Current Liabilities Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of FibroBiologics, Common Total Current Assets account and Total Current Liabilities. At this time, the significance of the direction appears to have very strong relationship.
Total Current AssetsTotal Current LiabilitiesDiversified AwayTotal Current AssetsTotal Current LiabilitiesDiversified Away100%
The correlation between FibroBiologics, Common's Total Current Assets and Total Current Liabilities is 0.89. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of FibroBiologics, Common Stock, assuming nothing else is changed. The correlation between historical values of FibroBiologics, Common's Total Current Assets and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of FibroBiologics, Common Stock are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Total Current Assets i.e., FibroBiologics, Common's Total Current Assets and Total Current Liabilities go up and down completely randomly.

Correlation Coefficient

0.89
Relationship DirectionPositive 
Relationship StrengthStrong

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.

Total Current Liabilities

Total Current Liabilities is an item on FibroBiologics, Common balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of FibroBiologics, Common Stock are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.
Most indicators from FibroBiologics, Common's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into FibroBiologics, Common current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroBiologics, Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
At this time, FibroBiologics, Common's Issuance Of Capital Stock is most likely to increase significantly in the upcoming years. The FibroBiologics, Common's current Enterprise Value is estimated to increase to about 1 B, while Selling General Administrative is projected to decrease to roughly 2.9 M.
 2021 2022 2023 2024 (projected)
Total Operating Expenses1.6M4.4M8.9M9.3M
Research Development521K1.1M2.4M1.3M

FibroBiologics, Common fundamental ratios Correlations

-0.690.77-0.94-0.15-0.99-0.91-0.670.85-0.94-1.0-1.00.95-0.9-0.83-0.84-1.0-0.370.230.91-0.94
-0.69-0.990.690.530.610.760.13-0.340.630.640.64-0.60.770.790.760.65-0.150.26-0.520.53
0.77-0.99-0.75-0.47-0.7-0.81-0.230.44-0.7-0.72-0.720.68-0.82-0.82-0.79-0.730.06-0.180.61-0.62
-0.940.69-0.750.290.90.970.52-0.730.990.920.92-0.80.950.880.940.920.21-0.08-0.720.94
-0.150.53-0.470.290.030.5-0.630.390.150.090.09-0.050.540.680.60.11-0.860.930.06-0.06
-0.990.61-0.70.90.030.860.76-0.910.921.01.0-0.970.840.750.761.00.48-0.35-0.950.94
-0.910.76-0.810.970.50.860.34-0.590.920.880.88-0.791.00.970.990.890.00.14-0.70.83
-0.670.13-0.230.52-0.630.760.34-0.960.620.720.72-0.720.30.140.210.70.94-0.88-0.770.78
0.85-0.340.44-0.730.39-0.91-0.59-0.96-0.8-0.88-0.880.86-0.55-0.41-0.47-0.87-0.80.710.88-0.91
-0.940.63-0.70.990.150.920.920.62-0.80.920.92-0.80.90.810.890.920.34-0.21-0.730.97
-1.00.64-0.720.920.091.00.880.72-0.880.921.0-0.970.860.780.791.00.43-0.29-0.940.94
-1.00.64-0.720.920.091.00.880.72-0.880.921.0-0.970.860.780.791.00.43-0.29-0.940.94
0.95-0.60.68-0.8-0.05-0.97-0.79-0.720.86-0.8-0.97-0.97-0.78-0.72-0.68-0.97-0.440.310.99-0.84
-0.90.77-0.820.950.540.841.00.3-0.550.90.860.86-0.780.980.990.87-0.050.19-0.680.8
-0.830.79-0.820.880.680.750.970.14-0.410.810.780.78-0.720.980.980.8-0.210.35-0.610.68
-0.840.76-0.790.940.60.760.990.21-0.470.890.790.79-0.680.990.980.81-0.130.27-0.570.77
-1.00.65-0.730.920.111.00.890.7-0.870.921.01.0-0.970.870.80.810.41-0.27-0.940.93
-0.37-0.150.060.21-0.860.480.00.94-0.80.340.430.43-0.44-0.05-0.21-0.130.41-0.99-0.530.54
0.230.26-0.18-0.080.93-0.350.14-0.880.71-0.21-0.29-0.290.310.190.350.27-0.27-0.990.41-0.42
0.91-0.520.61-0.720.06-0.95-0.7-0.770.88-0.73-0.94-0.940.99-0.68-0.61-0.57-0.94-0.530.41-0.8
-0.940.53-0.620.94-0.060.940.830.78-0.910.970.940.94-0.840.80.680.770.930.54-0.42-0.8
Click cells to compare fundamentals

FibroBiologics, Common Account Relationship Matchups

Currently Active Assets on Macroaxis

When determining whether FibroBiologics, Common is a strong investment it is important to analyze FibroBiologics, Common's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact FibroBiologics, Common's future performance. For an informed investment choice regarding FibroBiologics, Stock, refer to the following important reports:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroBiologics, Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroBiologics, Common. If investors know FibroBiologics, will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroBiologics, Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.55)
Return On Assets
(0.66)
Return On Equity
(2.68)
The market value of FibroBiologics, Common is measured differently than its book value, which is the value of FibroBiologics, that is recorded on the company's balance sheet. Investors also form their own opinion of FibroBiologics, Common's value that differs from its market value or its book value, called intrinsic value, which is FibroBiologics, Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroBiologics, Common's market value can be influenced by many factors that don't directly affect FibroBiologics, Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroBiologics, Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroBiologics, Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroBiologics, Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Trending Assets

PFLT
PennantPark Floating Rate
10.77  0.10  0.94 
ZM
Zoom Video Communications
84.62  0.02  0.02 
FDVA
Freedom Bank
10.65  -0.22  -2.02 
SPNT
Siriuspoint
14.62  0.12  0.83 
News Freq…Investor S…